Stereotaxis to Host Inaugural Innovation Day – Pioneering Endovascular Robotics
Stereotaxis (NYSE: STXS) has announced its inaugural Innovation Day on December 13, 2021, at 4:00 p.m. EST.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Stereotaxis (NYSE: STXS) has announced its inaugural Innovation Day on December 13, 2021, at 4:00 p.m. EST. This live webcast event will showcase the company's innovation pipeline with presentations from leadership and a Q&A session. Stereotaxis is recognized as a global leader in surgical robotics for minimally invasive endovascular intervention, having treated over 100,000 patients worldwide. Interested participants can register in advance at www.stereotaxis.com/innovation-day.
Details
News Market Reaction – STXS
The recorded move for STXS in the trading session of this news was -2.11%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
ST. LOUIS, Nov. 18, 2021 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced it will host an inaugural Innovation Day by live webcast on December 13. The event will include presentations of the company’s innovation pipeline by members of Stereotaxis leadership with a live Q&A session.
| What: | Stereotaxis Innovation Day – Pioneering Endovascular Robotics | |
| When: | Monday, December 13, 2021 at 4:00 p.m. EST (1:00 p.m. PST) | |
| Registration: | Please register in advance by visiting www.stereotaxis.com/innovation-day |
“We are excited to share Stereotaxis’ next wave of innovations and the transformative impact these innovations will have on the advancement of endovascular surgery,” said David Fischel, Chairman and CEO of Stereotaxis.
About Stereotaxis
Stereotaxis (NYSE: STXS) is a pioneer and global leader in innovative surgical robotics for minimally invasive endovascular intervention. Its mission is the discovery, development and delivery of robotic systems, instruments, and information solutions for the interventional laboratory. These innovations help physicians provide unsurpassed patient care with robotic precision and safety, expand access to minimally invasive therapy, and enhance the productivity, connectivity, and intelligence in the operating room. Stereotaxis technology has been used to treat over 100,000 patients across the United States, Europe, Asia, and elsewhere. For more information, please visit www.stereotaxis.com.
This press release includes statements that may constitute "forward-looking" statements, usually containing the words "believe”, "estimate”, "project”, "expect" or similar expressions. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially. Factors that would cause or contribute to such differences include, but are not limited to, the Company's ability to manage expenses at sustainable levels, acceptance of the Company's products in the marketplace, the effect of global economic conditions on the ability and willingness of customers to purchase its technology, competitive factors, changes resulting from healthcare policy, dependence upon third-party vendors, timing of regulatory approvals, the impact of pandemics or other disasters, and other risks discussed in the Company's periodic and other filings with the Securities and Exchange Commission. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release. There can be no assurance that the Company will recognize revenue related to its purchase orders and other commitments because some of these purchase orders and other commitments are subject to contingencies that are outside of the Company's control and may be revised, modified, delayed, or canceled.
Stereotaxis Contacts:
David L. Fischel
Chairman and Chief Executive Officer
Kimberly Peery
Chief Financial Officer
314-678-6100
investors@stereotaxis.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.